3/23
08:42 am
eprx
Eupraxia Pharmaceuticals (EPRX) is now covered by William Blair. They set an "outperform" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (EPRX) is now covered by William Blair. They set an "outperform" rating on the stock.
3/19
06:20 am
eprx
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
08:29 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
3/17
08:01 am
eprx
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
3/17
07:54 am
eprx
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
3/17
07:00 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Medium
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
3/12
09:03 pm
eprx
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Low
Report
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
2/21
02:04 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
Medium
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at
Wal
2/20
03:50 pm
eprx
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
2/20
03:10 pm
eprx
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Low
Report
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
2/19
02:18 am
eprx
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
High
Report
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
2/18
04:01 pm
eprx
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Medium
Report
Eupraxia Pharmaceuticals Announces Proposed Public Offering
1/15
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
1/9
08:02 am
eprx
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Neutral
Report
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
1/8
07:05 pm
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
1/8
09:53 am
eprx
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
High
Report
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
1/8
07:34 am
eprx
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
High
Report
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy